Early onset and long lasting protection in pigs provided by a classical swine fever E2-vaccine candidate produced in the milk of goats.
For vaccination against classical swine fever virus (CSFV), it is strongly desirable to induce a rapid and long lasting protection. At present, only live attenuated CSFV vaccines have shown early onset of protection, differing with the recombinant subunit-based vaccines reported so far. Recently, a new vaccine formulation based on E2 envelope viral glycoprotein produced in the milk of goats (E2his) has been shown to induce a highly protective response in pigs against CSFV infection. Pigs immunized with a single dose of this vaccine candidate, formulated as a water-in oil emulsion, elicited an effective response against CSF as early as 7 days post-vaccination. No severe CSF clinical signs were observed and no animals died although the challenge dose was 10(5)PDL(50) of a highly pathogenic CSFV strain. Noticeably, this response completely prevented CSFV infection in pigs when they were challenged under the same conditions 2 weeks after a single dose of the recombinant E2his vaccine formulation. A schedule consisting of a primary immunization with the same vaccine candidate, followed by a booster dose 2 weeks later induced a highly protective response against CSFV infection for as long as 9 months post-vaccination. These promising results demonstrate by far the feasibility of using the E2his-based vaccine in regional programs for preventing and controlling CSF.
Barrera
Maritza
M
National Center for Animal and Plant Health (CENSA), Apdo 10, San José de Las Lajas, Havana, Cuba.
Sánchez
Oliberto
O
Farnós
Omar
O
Rodríguez
María P
MP
Domínguez
Patricia
P
Tait
Henry
H
Frías
María
M
Avila
Mislay
M
Vega
Ernesto
E
Toledo
Jorge R
JR
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D001831:Body Temperature / Q000276:immunology; D006691:Classical Swine Fever / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006692:Classical Swine Fever Virus / Q000276:immunology*; D005260:Female; D006041:Goats; D008892:Milk / Q000276:immunology / Q000821:virology; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000235:genetics / Q000276:immunology; D013552:Swine; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*; D014766:Viremia / Q000276:immunology / Q000662:veterinary
D000914:Antibodies, Viral; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; D014765:Viral Vaccines